Trial · NCT06228963
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963, Phase 2, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma. Trials, record NCT06228963. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06228963
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
- NCT number
- NCT06228963
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- MALT Lymphoma of Stomach, Helicobacter Pylori Infection
- Interventions
- Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib, Triple therapy for eradication of Helicobacter Pylori
- First posted
- 2024-01-29
- Last updated
- 2024-02-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-months CR rate | up to 6 months | the ratio of numbers of patients with complete response to all the participants receiving treatment |
| Secondary | 3-months CR rate | up to 3 months | the ratio of numbers of patients with complete response to all the participants |
| Secondary | 2-year progression-free survival (PFS) | From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years | the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason |
| Secondary | 2-year event-free survival (EFS) | From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years | the period from the date of patients sign informed consent to the observed event for any reason |
| Secondary | 2-year overall survival rate | From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years | time between the date of patients sign informed consent and the date of death or the date of last follow-up time |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Throughout the treatment period, up to 6 months | Record the name of adverse events and number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Other | Exploratory biomarkers | Throughout the treatment period, up to 2 years | Biomarkers for predictive factors of efficacy at baseline or during the treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06228963
GET https://conductscience.org/api/trials/v1/NCT06228963/registered